A Phase 2 interventional study of DANYELZA and Sargramostim in High-risk Neuroblastoma, Neuroblastoma and Childhood Neuroblastoma, sponsored by Memorial Sloan Kettering Cancer Center. Recruiting at 1 site in United States. Open to participants aged 18 Months to 19 Years. Per ClinicalTrials.gov, last updated 2026-08-28.
Sponsored by Memorial Sloan Kettering Cancer Center · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing naxitamab in Neuroblastoma — 9 open to participants now, 12 under way, none of them phase 3. naxitamab · Neuroblastoma.
Among the 17 studies testing naxitamab in Neuroblastoma, this one is the 12th largest by planned enrollment, is one of 2 that started in 2024, is one of 11 in phase 2, reaches primary completion later than 8 of the 11 other live ones, and was the 13th registered.
676 studies on the registry are indexed under Neuroblastoma; 127 are open to participants now.
Browse Neuroblastoma studies →9 of the 17 studies testing naxitamab in Neuroblastoma are open now, in 7 countries. Recruiting first, the newest first:
Giselle Sholler · Sites in United States
Ages 1–30
Shaare Zedek Medical Center · Sites in Israel
Ages 12 mo–21 yrs
Steven DuBois, MD · Sites in United States
Ages 1–30
Giselle Sholler · Sites in United States
Ages 1–21
Sun Yat-sen University · Sites in China
Ages 12 mo+
By country, each count listing its studies:
naxitamab: first FDA approval 2020 (DANYELZA). What it is approved for, and how studies give it, is on its page →
Of the 104 Neuroblastoma studies recruiting now, 25 (24%) set no upper age limit and 74 (71%) stop at 75 or younger; 101 take children under 18; 3 take healthy volunteers.
This study: 18 Months to 19 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 12 · Phase 4 1
First in 2011; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 45 is above the median of 33 across 508 interventional studies indexed under Neuroblastoma.
Median enrollment 62 across the 17 interventional studies. Of the 4 that completed or were terminated, 2 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 17 have an industry lead sponsor. The 8 most frequent:
Memorial Sloan Kettering Cancer Center is the lead sponsor of 1,964 studies on the registry; 325 are open to participants now.
Of its 135 completed or terminated interventional studies of FDA-regulated products, 71 (53%) have results posted.
51 studies in Neuroblastoma by Memorial Sloan Kettering Cancer Center: 5 open now, 10 under way, none of them phase 3. Of 40 finished, 13 (33%) have results posted.
Among the 51 studies in Neuroblastoma by Memorial Sloan Kettering Cancer Center, this one is the 18th largest by planned enrollment of the 37 interventional ones that give a count, is the only one that started in 2024, is one of 22 in phase 2, and was the 51st registered.
Memorial Sloan Kettering Cancer Center’s Neuroblastoma studies by the year they started, since 1987.
5 of the studies testing naxitamab in Neuroblastoma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01757626Memorial Sloan Kettering Cancer CenterCombination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma | 2026-12 |
| NCT06013618Sun Yat-sen UniversityClinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma | 2026-12-31 |
| NCT03189706Memorial Sloan Kettering Cancer CenterStudy of Chemoimmunotherapy for High-Risk Neuroblastoma | 2027-06 |
| NCT06047535SciClone PharmaceuticalsNaxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Combined With Isotretinoin for Maintenance Treatment of Patients With High-Risk Neuroblastoma in First Complete Response. | 2027-06-15 |
| NCT07027748Steven DuBois, MDFeasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma | 2027-07-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 17 studies testing naxitamab in Neuroblastoma, from their registry updates:
Among Memorial Sloan Kettering Cancer Center’s 51 in Neuroblastoma:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to find out whether N10 chemotherapy is a safe and effective treatment for children with high-risk neuroblastoma.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Severe dysfunction of major organs, i.e., renal, cardiac, hepatic, neurologic, pulmonary, hematologic, or gastrointestinal toxicity >/= to grade 3
°Organ dysfunction due to direct effects of primary tumor or disease, or due to paraneoplastic syndromes associated with neuroblastoma, will not be considered in exclusion criteria. Similarly, complications of interventions to control above direct effects (e.g., - induced hyperglycemia or hypertension) will also not be considered in exclusion criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive 4 cycles of induction chemotherapy followed by a response-based intervention.
Biological: DANYELZA · Biological: Sargramostim · Drug: Cytoxan · Drug: Topotecan · Drug: Vincristine · Drug: Doxorubicin · Drug: Ifosfamide · Drug: Etoposide · Drug: Carboplatin · Drug: Irinotecan · Drug: Temozolomide · Radiation: Radiation Therapy
DANYELZA is a humanized monoclonal antibody of the IgG1 subclass
Also known as: Naxitamab
Yeast derived recombinant human Sargramostim (GM-CSF)
Also known as: granulocyte-macrophage colony-stimulating factor, GM-CSF
Cyclophosphamide is an alkylating agent related to nitrogen mustard
Also known as: Cyclophosphamide
Topotecan is a topoisomerase I-inhibitor that is a semisynthetic derivative of camptothecin.
Vincristine is an alkaloid isolated from Vinca rosea Linn (periwinkle).
Also known as: Oncovin
Doxorubicin is an anthracycline antibiotic
Also known as: Adriamycin
Ifosfamide is a structural analogue of cyclophosphamide
Also known as: Isophosphamide
Etoposide for Injection is available as a 20 mg/mL solution in sterile multiple dose vials (5 mL, 25 mL, or 50 mL each).
Also known as: VePesid, Etopophos, VP-16
Carboplatin is available in 50 mg, 150 mg, 450 mg, and 600 mg vials.
Also known as: Paraplatin
Irinotecan hydrochloride trihydrate (CPT-11) is a topoisomerase I inhibitor
Also known as: Camptosar
Temozolomide is administered intravenously
Also known as: Temodar
Between first and second cycle of antibody
Evaluate participant response
To assess the early Complete Response/CR rate in newly-diagnosed HR-NB patients.
Time frame: After 2 cycles of mAb-based therapy (each cycle is 21 days)
Plan to share: Yes — Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.
Started Jul 2024 (actual). Primary completion is estimated for Jul 2029, 60 months after the start.
Of 62 non-industry phase 2 interventional studies under Neuroblastoma, half reached primary completion within 74 months of starting (the median), counting those still running; a quarter within 52 and three quarters within 99. This study's planned 60 months is below that.
Counting every sponsor, half of 67 studies reached it within 74 months; a quarter within 52 and three quarters within 99.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Naxitamab · Sargramostim · Cyclophosphamide · Topotecan · Vincristine · Doxorubicin · Ifosfamide · Etoposide · Carboplatin · Irinotecan · Temozolomide
Memorial Sloan Kettering Cancer Center →